Diabetes Investigational Drug liraglutide

Diabetes Investigational Drug liraglutide More Effective at Lowering Blood Sugar Than glimepiride, Says Novo Nordisk
Novo Nordisk announced that new data presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sugar and weight after two years of treatment. In the study, 58% of patients treated with liraglutide 1.8 mg once daily reached and maintained the ADA's blood sugar target of HbA1C less than 7% versus 37% of patients treated with glimepiride 8 mg once daily. The LEAD™ 3 extension study also documented that treatment with liraglutide leads to early and lasting weight loss.